Tuesday, March 11

Tag: Seagen

How Biden’s Inflation Reduction Act Killed a Cancer Study
3Nov By adminNo Comments
Health

How Biden’s Inflation Reduction Act Killed a Cancer Study

President Biden has set an ambitious and laudable goal of reducing cancer mortality by half within 25 years, yet the Inflation Reduction Act (IRA) is working at cross purposes with that goal. See Seagen Inc. CEO David Epstein’s statement last week that the biotech company plans to scrap a new cancer drug study because of the law. The Food and Drug Administration approved Seagen’s antibody drug-conjugate Padcev in 2019 to treat locally advanced or metastatic bladder cancer that doesn’t respond to other therapies. Padcev uses an antibody that binds to specific proteins on cancer cells and directly delivers a payload of chemotherapy, which minimizes collateral damage to healthy non-cancerous cells.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1c...
Read More
Pfizer’s proposed $43 bn takeover of Seagen faces EU investigation
15Jul By adminNo Comments
Business

Pfizer’s proposed $43 bn takeover of Seagen faces EU investigation

By Samuel Stolton Pfizer Inc.’s proposed $43 billion takeover of Seagen Inc. will face an investigation from the European Union’s merger enforcer as the bloc continues to scrutinize large biotechnology deals.      Seagen disclosed in a regulatory filing late Friday that both firms have referred the deal to the European Commission, and the EU executive has accepted jurisdiction for investigating the proposal. The filings say that EU approval is a condition for the deal to close.    In the United States, the Federal Trade Commission will subject the proposed merger to an in-depth antitrust review, as is normal for major deals. The companies said when the takeover was announced that they expected close FTC scrutiny. Pfizer announced in March...
Read More